Goldman Sachs
MLYS icon

Goldman Sachs’s Mineralys Therapeutics MLYS Stock Holding History

Goldman Sachs’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$918K Buy
+33,900
New +$994K ﹤0.01% 5147

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Goldman Sachs's MLYS Position: Q1 2026 in Review

Goldman Sachs reduced its Mineralys Therapeutics (MLYS) stake by 46% in Q1 2026, selling an estimated $19.5M and leaving 785,043 shares worth $21.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Goldman Sachs first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $52.7M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Goldman Sachs held 785,043 shares of Mineralys Therapeutics worth $21.3M as of Q1 2026.
  • Goldman Sachs sold 665,890 Mineralys Therapeutics shares in Q1 2026, an estimated $19.5M.
  • Mineralys Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2375 holding.
  • Goldman Sachs first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Goldman Sachs's Mineralys Therapeutics position peaked at $52.7M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.